# Guidelines for the control of shigellosis, including epidemics due to *Shigella dysenteriae* type 1



#### WHO Library Cataloguing-in-Publication Data

World Health Organization.

Guidelines for the control of shigellosis, including epidemics due to Shigella dysenteriae 1.

1. Dysentery, Bacillary - prevention and control 2. Shigella dysenteriae - pathogenicity 3. Disease outbreaks - prevention and control 4. Guidelines I. Title.

NLM Classification: WC 282)

ISBN 924159330X

#### © World Health Organization 2005

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed by the WHO Document Production Services, Geneva, Switzerland.

## Acknowledgement

These guidelines were prepared during a workshop held at the Centre for Health and Population Research (ICDDR,B), Dhaka, Bangladesh, on 16-18 February 2004, that was supported by the WHO Department of Child and Adolescent Health and Development, the United States Agency for International Development Global Health Bureau, the Centre for Health and Population Research and the International Vaccine Institute.

#### Participants in this workshop were:

B. Agerberth, Stockholm, Sweden; A. Aidara Kane, Geneva, Switzerland; P.K. Bardhan, Dhaka, Bangladesh; B.A. Rhida, Tunis-Belvédère, Tunisia; C. Boye, Dakar-Fann, Senegal; N. Brandes, Washington, DC, USA; R. Breiman, Dhaka, Bangladesh; D.L. Brondi, London, United Kingdom; A. Brooks, Dhaka, Bangladesh; J. Carter, Nairobi, Kenya; W. Chaicumpa, Bangkok, Thailand; C.L. Chaignat, Geneva, Switzerland; C. de la Cruz, Manila, The Philippines; H. El Bushra, Cairo, Egypt; O. Fontaine, Geneva, Switzerland; P. Grimont, Paris, France; G.H. Gudmundsson, Reykjavik, Iceland; P. Guérin, Paris, France; M. Haque, Dhaka, Bangladesh; Abid Hossain, Dhaka, Bangladesh; Anowar Hossain, Dhaka, Bangladesh; P. Kalluri, Atlanta, USA; S. Kariuku, Nairobi, Kenya; K. Keddy, Johannesburg, South Africa; Kruy Sun Lay, Phnom Penh City, Cambodia; Kwai-Lin Thong, Kuala Lumpur, Malaysia; S. Lee, Seoul, South Korea; D. Legros, Geneva, Switzerland; J.C.L. Mwansa, Lusaka, Zambia; A. Naheed, Dhaka, Bangladesh; G.B. Nair, Dhaka, Bangladesh; L.K. Ng, Winnipeg, Canada; J.B. Ndihokubwayo, Harare, Zimbabwe; S.Q. Nizami, Karachi, Pakistan; G. Nylen, Copenhagen, Denmark; A. Pach, Seoul, South Korea; Lt. Gen. D. Raghunath, Bangalore, India; R. Raqib, Dhaka, Bangladesh; N. Rollins, Durban, South Africa; D.A. Sack, Dhaka, Bangladesh; C. Sadorge, Paris, France; M.A. Salam, Dhaka, Bangladesh; L. von Seidlein, Seoul, South Korea; K. Seonghan, Seoul, South Korea; D. Steele, Geneva, Switzerland; K.A. Talukder, Dhaka, Bangladesh; S. Wiseman, Washington, DC, USA; and S. Yamasaki, Osaka, Japan.

Special thanks to Dr D. Legros for preparing the draft of these guidelines and to Dr N.F. Pierce for editing them.

## Table of contents

Introduction	1
Epidemiology	2
The organism	2
Disease burden	
Endemic shigellosis	2
Epidemics caused by Sd1	3
The disease	3
Mode of transmission	3
Clinical presentation	3
Risk factors for severe disease and death	3
Diagnosis	4
Differential diagnosis	5
Shigellosis and HIV/AIDS	5
Surveillance	5
Reporting cases and detecting outbreaks of bloody diarrhoea	5
Laboratory surveillance	5
Prevention	7
Health education	7
Hand-washing	7
Water supply	
Disposal of human waste	8
Breastfeeding	9
Food safety	9
Vaccines	9
Management of patients with bloody diarrhoea	11
Antimicrobial therapy	11
Rehydration, feeding and other supportive care	
Preventing and treating dehydration	14
Feeding	14
Other supportive measures	14
Treatment of complications	15
Hypokalemia, hyponatremia and hypoglycemia	
Convulsions	15
Encephalopathy	16
Toxic megacolon	16

Haemolytic-uraemic syndrome	10
Intestinal perforation	16
Rectal prolapse	16
Preventing the spread of Shigella in health facilities	16
Sd1 outbreak preparedness and response	18
Sd1 outbreak preparedness	18
National treatment policy	19
Training health professionals	19
Stockpiling emergency supplies	19
Alert and confirmation of an outbreak	20
Response to an Sd1 outbreak	20
Patient care	21
Routine preventive measures	21
Specific preventive measures for epidemics	22
Epidemiological and laboratory surveillance	
Ineffective control measures	24
After an outbreak	26
Selected references	27
Annexes	
Annex 1 - Template for Investigation Report	29
Annex 2 - Some International Reference Laboratories	31
Annex 3 - Specimen Collection and Transport Methods	33
Annex 4 - Laboratory Identification of Shigella	37
Annex 5 - Antimicrobial Susceptibility Testing of Shigella	39
Annex 6 - Health Education Messages	43
Annex 7 - Making Water Safe for Drinking	45
Annex 8 - Building a VIP Latrine	47
Annex 9 - Rules for Safe Preparation of Food	
Annex 10 - Treatment Regimens for Ciprofloxacin and Zinc	49
Annex 11 - Classification and Treatment of Dehydration	50
Annex 12 - Preparation of Home Made Oral Rehydration Solution	51
Annex 13 - Feeding Practices During and After Diarrhoea	
Annex 14 - Preparation of Disinfecting Solutions	
Annex 15 - Check List for Epidemic Control	54
Annex 16 - List of Supplies Needed for the Management of 100 Patients	60
Annex 17 - List of Supplies for Laboratory Identification of Sd1	00
During an Outbreak	61
Annex 18 - Funeral Precautions	
Annex 19 - Daily Report Form and Hospital Admission Register	

## **Tables**

	Table 1:	Species and serogroups of Shigella	2
	Table 2:	Shigellosis: disease summary	
	Table 3:	Collection and transport of stool samples and testing antimicrobial sensitivity	6
	Table 4:	Preventive measures	10
	Table 5:	Antimicrobials for treatment of shigellosis	12
	Table 6:	Antimicrobials that should <b>not</b> be used for treatment of infections with <i>Shigella</i>	13
	Table 7:	Supportive care	15
	Table 8:	Chlorine solutions for disinfection	17
	Table 9:	Sd1 outbreak preparedness	21
	Table 10:	Response to an Sd1 outbreak	25
Fi	gures		
	Figure 1:	Management of shigellosis	12

## Introduction

Shigellosis is an acute invasive enteric infection caused by bacteria belonging to the genus *Shigella*; it is clinically manifested by diarrhoea that is frequently bloody. Shigellosis is endemic in many developing countries and also occurs in epidemics causing considerable morbidity and mortality. Among the four species of *Shigella*, *Shigella dysenteriae* type 1 (Sd1) is especially important because it causes the most severe disease and may occur in large regional epidemics. Major obstacles to the control of shigellosis include the ease with which *Shigella* spreads from person to person and the rapidity with which it develops antimicrobial resistance.

These guidelines are intended to assist national health authorities, public health officers and health-care providers, including members of international agencies and nongovernmental organizations (NGO), in their efforts to control both endemic and epidemic shigellosis. The text describes the epidemiology, clinical features and management of the disease, and measures to prepare for and control epidemics caused by Sd1.

The following definitions apply to terms used in this document:

- Bloody diarrhoea. This is a clinical diagnosis that refers to any diarrhoeal episode in which the loose or watery stools contain visible red blood. This does not include episodes in which blood is present in streaks on the surface of formed stool, is detected only by microscopic examination or biochemical tests, or in which stools are black owing to the presence of digested blood (melena). Although bloody diarrhoea has numerous causes, this simple definition is widely used in community-based surveillance for shigellosis.
- Dysentery. This has the same meaning as bloody diarrhoea. Although clinical texts often use this term to describe the syndrome of bloody diarrhoea with fever, abdominal cramps, rectal pain and mucoid stools, these feature do not always accompany bloody diarrhoea, nor do they necessarily define its aetiology or determine appropriate treatment.
- **Bacillary dysentery.** This is dysentery caused by *Shigella*. The term is often used to distinguish shigellosis from amoebic dysentery, caused by *Entamoeba histolytica*.
- Invasive diarrhoea. This refers to diarrhoea caused by bacterial pathogens, including *Shigella*, and some *Salmonella*, *E. coli* and *Campylobacter jejuni*, that invade the bowel mucosa, causing inflammation and tissue damage. When visible blood is present, the episode may also be termed dysentery or bloody diarrhoea.

Introduction 1

## **Epidemiology**

### The organism

Shigella are Gram-negative, non-motile bacilli belonging to the family Enterobacteriacae. The genus Shigella includes four species: S. dysenteriae, S. flexneri, S. boydii and S. sonnei, also designated groups A, B, C and D, respectively. The first three species include multiple serotypes. S. sonnei and S. boydii usually cause relatively mild illness in which diarrhoea may be watery or bloody. S. flexneri is the chief cause of endemic shigellosis in developing countries. Immunity is serotype-specific.

Sd1, also known as the Shiga bacillus, differs from other *Shigella* in four important ways:

- it produces a potent cytotoxin (Shiga toxin);
- it causes illness that is more severe, more prolonged, and more frequently fatal than is illness caused by other *Shigella*;
- resistance to antimicrobials occurs more frequently than among other Shigella; and
- it causes large, often regional, epidemics, frequently with high attack rates and high case fatality rates.

TABLE 1. Species and serogroups of Shigella				
Species	Serogroup	Serotypes		
S. dysenteriae	Α	1 - 15		
S. flexneri	В	1 - 6 (with 15 subtypes)		
S. boydii	С	1 - 18		
S sonnei	D	1		

All species of *Shigella* cause acute bloody diarrhoea by invading and causing patchy destruction of the colonic epithelium. This leads to the formation of micro-ulcers and inflammatory exudates, and causes inflammatory cells (polymorphonuclear leucocytes, PMNs) and blood to appear in the stool. The diarrhoeal stool contains 10<sup>6</sup>-10<sup>8</sup> *Shigellae* per gram. Once excreted, the organism is very sensitive to environmental conditions and dies rapidly, especially when dried or exposed to direct

预览已结束,完整报告链接和二维码如下:

https://www.yunbaogao.cn/report/index/report?reportId=5 29988

